Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cholecystokinin and the hormone concept

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Free testosterone and cardiometabolic parameters in men: comparison of algorithms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Serum insulin-like factor 3 levels are reduced in former androgen users suggesting impaired Leydig cell capacity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictors of Improvement in Quality of Life When Treating Hypothyroidism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Identification of a unique epigenetic profile in women with diminished ovarian reserve

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95%CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95%CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95%CI 0.01-0.25, p<0.05) and 0.38 min (95%CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12% (95%CI 0-23, p=0.05) with liraglutide and there was a trend towards 16% (95%CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.
OriginalsprogEngelsk
TidsskriftEndocrine Connections
Vol/bind6
Udgave nummer2
Sider (fra-til)89-99
Antal sider24
ISSN2049-3614
DOI
StatusUdgivet - 24 jan. 2017

ID: 49809786